StemCell Therapy

New DelhiAn anti-Covid consortium of experts with the assistance of Department of Biotechnology is working towards producing therapeutic antibodies against Covid-19.

In India, one such effort is being led by Vijay Chaudhary at the University of Delhi South Campus-Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), with the support of the Department of Biotechnology in the Ministry of Science and Technology.

Chaudharys group is isolating genes encoding antibodies, which can neutralise the SARS-CoV-2, using a large antibody library already available in-house as well as a library made from cells of patients who have recovered from COVID-19 infection.

These antibody genes will be used to produce recombinant antibodies in the laboratory, which, if successful in neutralising the virus, will become a perennial source of antibodies against this virus, both for prophylactic and therapeutic purposes.

This work is being undertaken as part of an Anti-Covid consortium under the leadership of Chaudhary and involving Amulya Panda at National Institute of Immunology and Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL).

Covid 19 is caused by the novel SARS coronavirus-2 (SARS-CoV-2) and it is resulting in many deaths. However, a large number of infected people are also recovering despite not having any specific treatment. This is because of antibodies produced within the body in response to the virus invasion.

Over the years, passive transfer of antibodies obtained from the plasma of convalescent patients cured of infection has been used for treatment of numerous disease conditions such as diphtheria, tetanus, rabies and ebola.

Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2, a statement by Department of Biotechnology said. (IANS)

See original here:
Anti-Covid consortium in India working on therapeutic antibodies - India New England

Latest Report onAgriculture Biotechnology Market

The report titled Global Agriculture Biotechnology Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Agriculture Biotechnology market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Agriculture Biotechnology market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Agriculture Biotechnology market is carefully analyzed and researched about by the market analysts.

Agriculture Biotechnology Market competition by top manufacturers/ Key player Profiled: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences

Request a sample copy of the report with Detail TOC and List of Figures @ https://www.alexareports.com/report-sample/692707

Global Agriculture Biotechnology Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2024. According to the latest report added to the online repository of Alexareports the Agriculture Biotechnology market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2024.

Agriculture Biotechnology Market Segment by Type covers: Biochips, Deoxy ribonucleic acid (DNS) sequencing, Genome editing tools, Ribonucleic acid interference (RNAI), Synthetic biology

Agriculture Biotechnology Market Segment by Application covers:Transgenic crops market, Synthetic biology-enabled products market

After reading the Agriculture Biotechnology market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Agriculture Biotechnology market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalAgriculture Biotechnology market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Agriculture Biotechnology market?What are the key factors driving the global Agriculture Biotechnology market size?Who are the key manufacturers in Agriculture Biotechnology market space?What are the market opportunities, market risk and market overview of the Agriculture Biotechnology market?What are sales, revenue, and price analysis of top manufacturers of Agriculture Biotechnology market?Who are the distributors, traders, and dealers of Agriculture Biotechnology market?What are the Agriculture Biotechnology market opportunities and threats faced by the vendors in the global Agriculture Biotechnology industries?What are sales, revenue, and price analysis by types and applications of Agriculture Biotechnology market?What are sales, revenue, and price analysis by regions of Agriculture Biotechnology industries?

GetExclusive discount on this report now at https://www.alexareports.com/check-discount/692707

Some of the Major Highlights of TOC covers:

Agriculture Biotechnology Regional Market Analysis

Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Revenue by RegionsAgriculture Biotechnology Consumption by RegionsAgriculture Biotechnology Segment Market Analysis (by Type)

Global Agriculture Biotechnology Production by TypeGlobal Agriculture Biotechnology Revenue by TypeAgriculture Biotechnology Price by TypeAgriculture Biotechnology Segment Market Analysis (by Application)

Global Agriculture Biotechnology Consumption by ApplicationGlobal Agriculture Biotechnology Consumption Market Share by Application (2014-2020)Agriculture Biotechnology Major Manufacturers Analysis

Agriculture Biotechnology Production Sites and Area ServedProduct Introduction, Application and SpecificationAgriculture Biotechnology Production, Revenue, Ex-factory Price and Gross Margin (2014-2020)Main Business and Markets Served

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/692707

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

See the rest here:
(2020-2025) Agriculture Biotechnology Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue, Manufacturers...

Puma Biotechnology, Inc.'s (NASDAQ:PBYI): Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. The US$283m market-cap company announced a latest loss of -US$75.6m on 31 December 2019 for its most recent financial year result. As path to profitability is the topic on PBYIs investors mind, Ive decided to gauge market sentiment. In this article, I will touch on the expectations for PBYIs growth and when analysts expect the company to become profitable.

Check out our latest analysis for Puma Biotechnology

PBYI is bordering on breakeven, according to the 8 Biotechs analysts. They anticipate the company to incur a final loss in 2021, before generating positive profits of US$11m in 2022. So, PBYI is predicted to breakeven approximately 2 years from now. What rate will PBYI have to grow year-on-year in order to breakeven on this date? Using a line of best fit, I calculated an average annual growth rate of 62%, which is extremely buoyant. If this rate turns out to be too aggressive, PBYI may become profitable much later than analysts predict.

NasdaqGS:PBYI Past and Future Earnings April 8th 2020

Underlying developments driving PBYIs growth isnt the focus of this broad overview, however, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing I would like to bring into light with PBYI is its debt-to-equity ratio of over 2x. Typically, debt shouldnt exceed 40% of your equity, which in PBYIs case, it has significantly overshot. Note that a higher debt obligation increases the risk in investing in the loss-making company.

There are too many aspects of PBYI to cover in one brief article, but the key fundamentals for the company can all be found in one place PBYIs company page on Simply Wall St. Ive also put together a list of key aspects you should further research:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Follow this link:
Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven? - Yahoo Finance

For the readers interested in the stock health of Vir Biotechnology, Inc. (VIR). It is currently valued at $33.19. When the transactions were called off in the previous session, Stock hit the highs of $38.74, after setting-off with the price of $36.5. Companys stock value dipped to $32.15 during the trading on the day. When the trading was stopped its value was $29.00.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -55.74% during the 52-week period from high price, and 184.91% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 130.62%, having the revenues showcasing 140.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.21B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 22.19, with a change in the price was noted +19.48. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +146.80% for the period of last 100 days, recording 572,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 28.28%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.94%. In the last 20 days, the companys Stochastic %K was 11.97% and its Stochastic %D was recorded 11.37%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 130.62%. The shares increased approximately by 1.54% in the 7-day charts and went up by -15.45% in the period of the last 30 days. Common stock shares were driven by 140.86% during last recorded quarter.

Here is the original post:
This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low - The InvestChronicle

EIDD-2801, an oral broad-spectrum antiviral proceeding into Clinical Trials

ATLANTA and MIAMI, April 6, 2020 /PRNewswire/ -- Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application by Drug Innovation Ventures at Emory (DRIVE), LLC, wholly owned by Emory University, for an orally available antiviral compound, EIDD-2801, exclusively licensed to Ridgeback Biotherapeutics, LP (Ridgeback), a closely held biotechnology company. This action by the FDA allows Ridgeback to initiate human clinical testing of EIDD-2801 in the United States.

"We are thankful to FDA Commissioner Dr. Steven Hahn and his team at the Anti-Viral Division for the unprecedented speed in reviewing our submission, the guidance and the highly collaborative process that ensures this promising drug can advance into the clinical development as fast as possible," said Wendy Holman, Chief Executive Officer of Ridgeback. "We also appreciate the guidance we have received from the Assistant Secretary of Preparedness and Response (ASPR), including discussions that occurred months before COVID-19 first emerged, to help Emory/DRIVE advance the development of EIDD-2801 as quickly as possible to address this global pandemic."

EIDD-2801 prevents the replication of SARS-CoV-2, the virus that causes COVID-19, and has shown potent activity against SARS-CoV and MERS-CoV in animal models of infection. In addition to coronaviruses, EIDD-2801 has broad spectrum activity against a number of diseases of public health concern, including influenza, chikungunya, Ebola, and equine encephalitis (VEE and EEE). The antiviral is orally available and, in addition to COVID-19, is being developed for the treatment of seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).

"FDA's prompt approval of our IND allows us to initiate human testing for EIDD-2801 as quickly as possible," says George Painter, Ph.D., director of the Emory Institute for Drug Development (EIDD) and CEO of DRIVE. "We are grateful to our collaborators for helping us to assemble this application quickly, and to the FDA for expediting the process. An orally available antiviral medication would be a critical weapon for fighting COVID-19."

Ridgeback and DRIVE have established a partnership to advance EIDD-2801 through clinical development and to optimize availability during the current COVID-19 pandemic. EIDD-2801 was exclusively licensed to Ridgeback in March 2020.

"We look forward to our continued work with the highly experienced drug development team at DRIVE and the dedicated medical, public health and governmental personnel who are on the frontlines of this pandemic in the United States and abroad," says Wendy Holman, CEO of Ridgeback Biotherapeutics. "The ability to deliver promising treatments to patients in need is what makes us excited to come to work every day. Ridgeback brings its unique perspective, honed by our success developing an Ebola therapeutic during the 2018-2020 outbreak in the DR Congo, to help advance EIDD-2801 for the treatment of diseases that are critical to pandemics and global health."

About EIDD-2801:

EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. In animal studies of two distinct coronaviruses (SARS-CoV1 and MERS), EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. The development of EIDD-2801 has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), under contract numbers HHSN272201500008C and 75N93019C00058, and from the Defense Threat Reduction Agency (DTRA), under contract numbers HDTRA1-13-C-0072 and HDTRA1-15-C-0075.

About Ridgeback Biotherapeutics LP:

Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company focused on orphan and infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions. Ridgeback is in the process of completing a Biologics Licensing Application with the Food & Drug Administration for mAb114 (ansuvimab) for the treatment of Ebola. Ansuvimab development has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00059 and 75A50120C0009.

About DRIVE:

DRIVE is a non-profit LLC wholly owned by Emory University and started as an innovative approach to drug development. Operating like an early stage biotechnology company, DRIVE applies focus and industry development expertise to efficiently translate discoveries to address viruses of global concern. DRIVE's mission is to discover and develop antiviral drugs for emerging infections, pandemic threats, and biodefense (e.g. COVID-19, swine flu, bird flu, dengue, chikungunya, Ebola, Zika, and viral encephalitis). Because these diseases are major threats, antiviral drugs are critically needed to treat them; however, they are generally not profitable enough for industry to pursue, and thus are considered neglected diseases. DRIVE is unique in that it brings industry expertise to the assets of a leading research University to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. DRIVE's executive team, led by George Painter, has over three decades of drug development experience within both large pharmaceutical and biotechnology companies, including leading the development of multiple FDA approved antivirals to treat HIV and Influenza, among other viral diseases, including AZT and Relenza.

About Defense Threat Reduction Agency:

The Defense Threat Reduction Agency (DTRA) was formally established on October 1, 1998. DTRA enables the Department of Defense, the United States Government and International partners to counter and deter weapons of mass destruction and improvised threat networks. As a Combat Support Agency and a Defense Agency, DTRA's mission is to counter the threats posed by the full spectrum of weapons of mass destruction (WMD), including chemical, biological, radiological, nuclear, and high-yield explosives; counter the threats posed by the growing, evolving categories of improvised threats, including improvised explosive devices, car bombs and weaponized consumer drones, as well as the tactics, technologies and networks that put them on the battlefield; and ensure the U.S. military maintains a safe, secure, effective and credible nuclear weapons deterrent.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

SOURCE Ridgeback Biotherapeutics LP

See the rest here:
FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19 - BioSpace

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported Timothy P. Walbert, Chairman, President and CEO of Horizon Therapeutics plc, will succeed Chad Mirkin, Ph.D. as Chairman of Exicures Board of Directors. Dr. Mirkin, who will remain on the Board, is stepping down as Chairman due to his responsibilities at Northwestern University, where he is Professor and Director of the International Institute for Nanotechnology.

Tim Walbert has served as the president and chief executive officer of Horizon Therapeutics since 2008 and has served as chairman of its board of directors since 2010. Prior to joining Horizon, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company acquired by Takeda America Holdings, Inc. in 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biotechnology company. Mr. Walbert was also divisional vice president and general manager of immunology, where he led the global development and launch of the multi-indication biologic HUMIRA at Abbott, now AbbVie. Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, PA. He serves as chairman of the board of Zyla Life Sciences, co-chairman of the board of MATTER and serves on the board of the Illinois Biotechnology Innovation Organization (iBIO), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is a member of the Illinois Innovation Council, the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College.

Exicure is poised to change pharmaceutical development by opening up the field of digital medicine with its proprietary spherical nucleic acid (SNA) technology. Exicures existing programs and pipeline are promising, and the Company has many untapped therapeutic areas yet to be tackled. I look forward to working with the Exicure team to advance the Companys current clinical programs and take the Company into its next stage of development, while continuing to build its pipeline of new therapeutic candidates, said Mr. Walbert.

It has been a pleasure to serve as Chairman since we founded the company in 2011 and to help guide Exicure, said Dr. Mirkin. We have created a clinically-focused company with growing opportunities in neurology and an asset in immuno-oncology that is looking promising in clinical trials for several indications. The platform and team are strong and the potential opportunities are significant. As we continue to execute on our strategy and bring candidates through the clinic into commercialization, Tims experience and leadership in this area will be extremely valuable.

Under Chads leadership, we built a leading platform company focused on developing therapeutics based on our technology, initiated a clinical program (XCUR-FRN) in Friedreichs ataxia, advanced our immuno-oncology candidate AST-008 into Phase 2 clinical trials, entered into an exciting partnership with Allergan in hair loss disorders and finished 2019 with $110 million of cash on hand, said Dr. David Giljohann, Chief Executive Officer of Exicure. I am looking forward to Tims leadership as we continue to grow Exicure, concluded Dr. Giljohann.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNAbased therapeutic candidate, for the treatment of Friedreichs ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and also has an office in Cambridge, MA.

For more information, visit Exicures website at http://www.exicuretx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact could be deemed forward looking including, but not limited to, statements about the companys business strategy and plans, including its leadership in the field of digital medicine and development of product candidates based on its proprietary SNA technology and the companys transition from the clinic to commercialization; the advancement of the companys pipeline and product candidates; the potential of the companys collaborations and R&D efforts; and anticipated market opportunities for the companys product candidates in neurology and in immuno-oncology. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update these forward-looking statements. Forward-looking statements are based on managements current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risks that the COVID-19 pandemic may disrupt the companys business and/or the global healthcare system more severely than anticipated, which may have the effect of further delaying our ability to enroll and complete the companys ongoing Phase 1b/2 clinical trial, unexpected costs, charges or expenses that reduce cash runway; that the companys pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments and the ability of Exicure to protect its intellectual property rights. Furthermore, data from preclinical studies often fails to be indicative of outcomes in human trials. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Exicure undertakes no duty to update this information, except as required by law.

Continue reading here:
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board - Business Wire

Molecular weight markers are used to calculate sample molecular weights in the medical research arena. In addition, these markers play a vital role in the monitoring of the progress of an electrophoretic run in separation and analysis of macromolecules. Molecular weight markers include RNA, DNA, and protein markers.

The global molecular weight market is categorized on the basis of applications, products, end users, and staining procedures. Based on the type of applications, the report comprises protein and nucleic acid applications. The protein application segment is further subsegmented into gel extraction and Western blotting applications. Protein application is the fastest-growing segment in the molecular weight marker market. Nucleic acid applications include polymerase chain reaction (PCR), Northern blot, sequencing, molecular cloning, and Southern blot. The nucleic acid segment holds the largest market share in the global molecular weight marker market.

Request to Sample report @ https://www.persistencemarketresearch.com/samples/4385

On the basis of product, the report covers protein and RNA and DNA markers. These products are categorized on the basis of their marker sizes. The protein and RNA markers sizes included in the report are below 10 kilo Dalton (kDa), 10 kDa to 100 kDa, 100 kDa to 200 kDa, and above 200 kDa markers. The DNA markers sizes included in the report are below 50 base pair (bp), 50 bp to 100 bp, 100 bp to 1 kilo base pair (kb), 1 kb to 5 kb, and above 5 kb.

On the basis of end user, the global molecular weight marker market report is segmented into biotechnology and pharmaceutical companies, academic research institutes, and contract research organizations. The staining segment is further subsegmented into unstained, prestained, and specialty markers.

Request PMR insights on measuring the impact of COVID-19 coronavirus across industries.

In terms of geography, North America dominates the global molecular weight marker market. This is due to increased awareness about therapeutic applications of molecular biomarkers in disease management in the region. In addition, improved life science infrastructure has also propelled the growth of the molecular weight marker market in the region. The U.S. represents the largest market for molecular weight markers in North America, followed by Canada. In Europe, Germany, France, and the U.K. hold major shares of the molecular weight marker market. The molecular weight marker market in Asia too, is expected to show high growth rates in the next five years. This is due to the proliferation of biotechnology companies setting up manufacturing facilities in the region. Moreover, the growing life science infrastructure is also driving the growth of the market in the region. India, China, and Japan are expected to be the fastest-growing markets for molecular weight markers in Asia.

Request to View TOC @ https://www.persistencemarketresearch.com/toc/4385

The increasing prevalence of chronic diseases that require molecular biomarkers for their treatment is a key driver of the global molecular weight marker market. In addition, increasing government supports in the form of funding in the life science arena is also supporting the growth of the global molecular weight marker market. Increasing investment in R&D in biotechnology and pharmaceutical sectors and innovative applications of molecular weight markers have fueled the growth of this market. However, lack of skilled healthcare professionals obstructs the growth of the global molecular weight marker market.

Increasing numbers of mergers and acquisitions between biotechnology and pharmaceutical companies is a key trend of the global molecular weight marker market.

The major companies operating in this market are ,

For in-depth competitive analysis, buy [emailprotected] https://www.persistencemarketresearch.com/checkout/4385

See more here:
Molecular Weight Marker Market Opportunities, Challenges, Growth, Revenue and Forecast 2015 to 2021 - Daily Science

The "Agricultural Biotechnology: Emerging Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The study scope includes key agricultural biotechnology tools (i.e., next-generation DNA sequencing, biochips, RNA interference, synthetic biology tools, and gene editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

The report analyzes these technologies and products to determine present and future market sizes, and to forecast growth from 2019 through 2024. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status and market driving forces.

The research provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS and microarray companies); major seed companies; biotech trait companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2018 and 2019.

96 agricultural and biotechnology companies are profiled in this report.

The report includes:

Market Insights

Global megatrends are driving the need for higher agricultural yields, creating strong tailwinds for innovative seed traits and biological pesticides and stimulants.

World population growth, coupled with rising incomes, lead to consumption of higher-quality foods, including meat. This, in turn, creates higher consumption of feed crops, including maize, soy, and wheat. At the same time, the total acreage of arable land available for producing crops is under pressure from a range of forces, including growing populations, urbanization, and global warming.

These global forces are creating leverage in the industry to increase productivity and crop yields. Biotechnology provides strategic tools for the agricultural industry to meet these market demands. This report examines the role of these technologies in agriculture and quantifies their market impact.

Reasons for Doing the Study

Agriculture is a fundamental and strategic component of a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields and other desirable traits. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader. The report does this by examining the main product applications and markets, thereby helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments, in order to help the reader better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, gene editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Technology Background

Chapter 5 Agricultural Biotechnology Applications

Chapter 6 DNA Read, Write and Edit Industries

Chapter 7 Acquisitions and Strategic Alliances

Chapter 8 Agricultural Biotechnology Markets

Chapter 9 Patents

Chapter 10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/fwyt4b

View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005159/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read more:
The Agricultural Biotechnology Industry 2020: Emerging Technologies and Global Markets - ResearchAndMarkets.com - Yahoo Finance

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Generation Bio and Vir Biotechnology (Nasdaq: VIR) today announced a collaborative research agreement to explore the potential for Generation Bios non-viral gene therapy platform to extend the impact and reach of Virs current or future human monoclonal antibodies (mAb) against SARS-CoV-2, the virus responsible for COVID-19. Generation Bios technology has the potential to deliver genetic information directly to cells without the use of adeno-associated viruses (AAV), in effect instructing the patients body to produce the antibody itself.

The companies believe that this technology, coupled with Virs potent neutralizing antibodies, has the potential to provide effective, long-lasting protection against SARS-CoV-2. Virs leading antibody was isolated from a SARS-CoV-1 recovered patient and potently neutralizes SARS-CoV-2. Vir believes that this approach can potentially provide broad and longer-lasting protection.

Together, we believe we can develop long-lasting therapies suitable for population-wide prevention and treatment, said Generation Bio President and CEO Geoff McDonough, M.D. We are moving with urgency to explore leveraging our platform to build protection against COVID-19 for the long term.

Generation Bios proprietary non-viral gene therapy platform is designed to enable production of target proteins from a patients own cells. This approach may allow the patient to maintain stable levels of antibody expression for years, providing continuous protection against the target virus. In addition, the companies intend to leverage Generation Bios scalable manufacturing process to potentially extend the reach of Virs monoclonal antibodies to a greater number of patients.

We are eager to bring our antibodies to patients as quickly as possible, and should they work, to make them available to as many patients as quickly as possible. We are excited to explore the potential of ceDNA in an infectious disease setting and our anti-SARS-CoV-2 program offers a way to do that, said George Scangos, Ph.D., CEO of Vir. Both companies are highly motivated to make meaningful contributions to stopping this disease and we look forward to a productive collaboration with Generation Bio.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The companys non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patients life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.

About Virs Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in the Democratic Republic of Congo), hepatitis B virus, influenza A, SARS-CoV-2, malaria, and others.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus, and tuberculosis. For more information, please visit http://www.vir.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, believe, plan, anticipate, estimate, explore, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of Virs collaboration with Generation Bio, the ability of ceDNA to deliver and support the production of antibodies against SARS-CoV-2, Virs efforts to identify potential therapies for SARS-CoV-2, and its ability to address the COVID-19 pandemic. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in administering mAbs against SARS-CoV-2, difficulties in scaling the manufacturing process to extend the reach of Virs monoclonal antibodies, and challenges in accessing manufacturing capacity. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Link:
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of...

The recent performance of Vir Biotechnology (NASDAQ:VIR) stock in the market spoke loud and clear to investors as VIR saw more than 784.19K shares in trading volumes in the last trading session, way higher than the average trading volume of 784.19K shares by far recorded in the movement of Vir Biotechnology (VIR). At the time the stock opened at the value of $32.50, making it a high for the given period, the value of the stock jumped by 7.19%. After the increase, VIR touched a low price of $31.01, calling it a day with a closing price of $32.00, which means that the price of VIR went 1.8 below the opening price on the mentioned day.

Given the most recent momentum in the market in the price movement of VIR stock, some strong opinions on the matter of investing in the companys stock started to take shape, which is how analysts are predicting an estimated price of $26.33 for VIR within consensus. The estimated price would demand a set of gains in total of -123771.64%, which goes higher than the most recent closing price, indicating that the stock is in for bullish trends. Other indicators are hinting that the stock could reach an outstanding figure in the market share, which is currently set at 100.33M in the public float and 3.51B US dollars in market capitalization.

When it comes to the technical analysis of VIR stock, there are more than several important indicators on the companys success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. This value may also indicate that the stock will go sideways rather than up or down, also indicating that the price could stay where it is for quite some time. When it comes to Stochastic reading, VIR stock are showing 18.57% in results, indicating that the stock is neither overbought or oversold at the moment, providing it with a neutral within Stochastic reading as well. Additionally, VIR with the present state of 200 MA appear to be indicating bullish trends within the movement of the stock in the market. While other metrics within the technical analysis are due to provide an outline into the value of VIR, the general sentiment in the market is inclined toward positive trends.

With the previous 100-day trading volume average of 1.01 million shares, iStar (STAR) recorded a trading volume of 1.02 million shares, as the stock started the trading session at the value of $9.95, in the end touching the price of $10.66 after jumping by 7.14%.

STAR stock seem to be going ahead the lowest price in the last 52 weeks with the latest change of 94.53%.Then price of STAR also went backward in oppose to its average movements recorded in the previous 20 days. The price volatility of STAR stock during the period of the last months recorded 15.22%, whilst it changed for the week, now showing 14.65% of volatility in the last seven days. The trading distance for this period is set at -11.12% and is presently away from its moving average by -23.73% in the last 50 days. During the period of the last 5 days, STAR stock gain around 48.47% of its value, now recording a dip by -19.24% reaching an average $13.20 in the period of the last 200 days.During the period of the last 12 months, iStar (STAR) dropped by -26.53%.

According to the Barcharts scale, the companys consensus rating fall to 3.50 from 4.00, showing an overall improvement during the course of a single month.

STAR shares recorded a trading volume of 659503 shares, compared to the volume of 1.10M shares before the last close, presented as its trading average. With the approaching 14.65% during the last seven days, the volatility of STAR stock remained at 15.22%. During the last trading session, the lost value that STAR stock recorded was set at the price of $10.66, while the lowest value in the last 52 weeks was set at $5.48. The recovery of the stock in the market has notably added 94.53% of gains since its low value, also recording -32.53% in the period of the last 1 month.

Continue reading here:
What Will Eventually Wobble Vir Biotechnology (VIR), iStar (STAR) - US Post News

PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune today announced its financial results for the full year ended December 31, 2019 and provided a business update.

Fourth Quarter 2019 and Recent Business Highlights

We have made significant progress over the last year as we transitioned to a public company, strengthened our partnerships with leaders in immuno-oncology, such as Merck and National Cancer Institute and reported encouraging human data from our lead program, PDS0101, commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotechnology. As we forge ahead in 2020, we look forward to leveraging the highly encouraging Phase I human clinical outcome data, which demonstrated complete lesion regression in 60% of evaluable patients with cervical intraepithelial neoplasia (CIN) and human papillomavirus (HPV) within 1-3 months of treatment. These results support our combination approach in our upcoming clinical trials and provide evidence that PDS0101 could be essential in expanding the clinical efficacy of checkpoint inhibitors and improving clinical outcomes for patients.

With a strengthened balance sheet, we look forward to initiating three studies, including; a Phase 2 combination study to evaluate PDS0101 in combination with KEYTRUDA in the first line treatment of metastatic head and neck cancer, a Phase 2 study to evaluate PDS0101 in combination with two promising immune-modulating agents in advanced HPV-associated cancers with the NCI and a Phase 2a study to evaluate the combination of PDS0101 and chemoradiation in patients with locally advanced cervical cancer. We remain committed to developing our novel Versamune platform in collaboration with our partners and would like to thank our shareholders for their continued support, concluded Dr. Bedu-Addo.

Full Year 2019 Financial Review

For the year ended December 31, 2019, the net loss was approximately $6.9 million, or $1.44 per basic and diluted share. This compares to a net loss of approximately $3.8 million, or $1.15 per basic and diluted share for the year ended December 31, 2018.

For the year ended December 31, 2019, research and development expenses increased approximately 634% to approximately $6.1 million compared to approximately $0.8 million in the prior year. The increase is primarily attributable to an increase in external expenses for clinical studies, internal R&D personnel costs, non-cash stock-based compensation and departmental costs.

For the year ended December 31, 2019, general and administrative expenses increased approximately 294% to approximately $11.0 million compared to approximately $2.8 million in the prior year. The increase was due to increases in personnel costs, non-cash stock-based compensation, facilities costs, D&O insurance costs, legal fees, professional fees and other operating expenses.

For the year ended December 31, 2019, total operating expenses increased approximately 477% to approximately $21.0 million compared to approximately $3.6 million in the prior year.

As of December 31, 2019, the Companys cash balance was approximately $12.2 million. This amount does not include the approximately $11.9 million in net proceeds after deducting underwriting discounts and commissions, not including other offering expenses from PDS Biotechs underwritten public offering including the full exercise of the underwriters overallotment option, which closed in February.

About PDS Biotechnology

PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotech is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechs pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with the chemoradiotherapy, which is the standard of care.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; potential adverse reactions or changes to business relationships resulting from the resignation of the Companys Chief Financial Officer or the Companys ability to find a replacement Chief Financial Officer; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

(Financial Statements to Follow)

PDS BIOTECHNOLOGY CORPORATION and Subsidiaries

Consolidated Balance Sheets

PDS BIOTECHNOLOGY CORPORATION and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

Continued here:
PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update - BioSpace

Agricultural Biotechnology Markethas recently added by Qurate Research to its vast repository. This intelligence report includes investigations based on Current scenarios, Historical records, and future predictions. This includes factors such as market size, market share, market segmentation, significant growth drivers, market competition, different aspects impacting economic cycles in the market, demand, expected business up-downs, changing customer sentiments, key companies operating in the Agricultural Biotechnology Market, SWOT analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Thus, helping the companies to understand the threats and challenges in front of the businesses. Agricultural Biotechnology Market is showing steady growth and CAGR is expected to improve during the forecast period.

Prominent Players Profiled in the Report are

SyngentaDuPontMonsantoADAMA Agricultural SolutionsBASFBayer CropScienceCertis USADow AgroSciencesMycogen SeedPerformance PlantsKWS SAATEvogeneRubiconVilmorinGlobal Bio-chem Technology

Market by TypeMolecular MarkersVaccinesGenetic EngineeringTissue CultureMolecular DiagnosticsOthers

Market by ApplicationTransgenic Crops/SeedsBiopesticidesOthers

The Agricultural Biotechnology market report includes comprehensive information about the markets major competitors, including various organizations, companies, associations, suppliers and manufacturers competing for production, supply, sales, revenue generation, and after-sales performance expectations. The bargaining power of numerous vendors and buyers have also been included in the research report

Agricultural Biotechnology Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

Key Question Answered in Report.

Overview of the chapters analysing the global Agricultural Biotechnology Market in detail:

See more here:
Agricultural Biotechnology Market: Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2025 - The Fuel Fox

Sorrento Therapeutics Inc (SRNE) is near the bottom in its industry group according to InvestorsObserver. SRNE gets an overall rating of 31. That means it scores higher than 31 percent of stocks. Sorrento Therapeutics Inc gets a 16 rank in the Biotechnology industry. Biotechnology is number 13 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Sorrento Therapeutics Inc (SRNE) stock is trading at $1.86 as of 10:47 AM on Monday, Mar 30, an increase of $0.05, or 2.82% from the previous closing price of $1.81. The stock has traded between $1.80 and $1.94 so far today. Volume today is low. So far 1,628,594 shares have traded compared to average volume of 7,024,900 shares.

To screen for more stocks like SRNE click here.

See the rest here:
Is Sorrento Therapeutics Inc (SRNE) Stock Near the Top or Bottom of the Biotechnology Industry? - InvestorsObserver

Source

A year ago, I published an article on the iShares Nasdaq Biotechnology ETF (IBB), in which I dismissed the thought that IBB is the best fund to play the expected growth of the biotech sector. Since then, the fund has outperformed the S&P 500 Index by 3%.

Source: Seeking Alpha

I introduced investors to SPDR Biotech ETF (XBI), which I thought would outperform IBB because of its high concentration on small-cap stocks representing this business sector. Below is a comparison of returns between these two funds and the broad market in the last 12 months.

Data by YCharts

IBB has outperformed both the market and XBI over the last 12 months. However, up until the beginning of 2020, XBI had provided better returns than both the index and IBB, which was consistent with my expectations.

Twelve months and a pandemic later, I believe IBB is the best fund to hold for the next 12 months for reasons that are discussed below.

The major catalyst that would drive healthcare stocks higher in the next few months is the possibility of developing a vaccine or a drug to fight the novel coronavirus. However, such a product is unlikely to be invented by a small biotech company. This is not to say that the chances of such an occurrence are nil, but collectively, the big names in the industry have a better chance of finding a cure.

Here is a list of companies that are working to develop a cure for COVID-19 and their market capitalizations.

Source: MarketWatch

As evident from this data, the majority of companies who are actively working to develop a cure are billion-dollar companies. Governments and other responsible authorities, on the other hand, prefer to work with these companies because of their strong track record of previously working with state authorities to fight pandemics and other outbreaks.

IBB is a fund that primarily invests in large-cap biotech stocks, making the fund tailor-made to benefit from the expected surge in healthcare stock prices once further developments are announced of the fight against COVID-19.

IBB market-cap data

Source: Morningstar

The exposure to small and micro-cap biotech stocks are non-existent, which is a characteristic I did not enjoy a year back. However, the outbreak of the novel coronavirus, in my opinion, has changed the healthcare investing landscape considerably and tilted the odds in favor of large companies.

The top-10 holdings of IBB further highlight that the fund is invested in companies that are already researching for a product to fight the virus.

Source: Seeking Alpha

The thinking behind many investors is that the spread of COVID-19 will come to an end in the next couple of months, paving the way for global economic growth to return to its normalcy. However, things might be a bit more different than that. Even if the United States, along with other regions that are hammered by the virus, curb the spread of the virus, the repercussions of the pandemic will be felt throughout 2020.

Biotechnology companies will continue with their effort to develop a cure and different stages of their clinical trials will unfold for many months or years to come. Therefore, healthcare stocks are likely to be driven by pandemic-related developments for the entire year.

Is buying IBB better than buying the one company that will, for sure, develop a vaccine successfully to put an end to the novel coronavirus? Most certainly not, but no investor would be able to predict what company or companies would be successful in their efforts. Identifying which company would win the race and become the first to develop such medicine is even more complex. Therefore, an investment in IBB seems to have the best risk-reward profile to play the uncertainty, while gaining necessary exposure to the biotechnology sector.

Even if things continue to go South and none of the companies emerge victorious in this race to find a cure for COVID-19, the billion-dollar companies can still survive and reward investors in the long run, as opposed to a small-cap company whose stock price has shot up over the last few months based on expectations for a successful trial to fight the novel coronavirus. Almost all component companies of IBB have deep pipelines that could bring in billions of dollars in revenue in the coming years. Therefore, an investment in IBB is a less risky bet on the highly volatile biotech sector. This makes IBB even more attractive.

Biotech stocks are not for everyone because of the significant level of business uncertainty. An investor who is keen to gain exposure to the expected surge in healthcare stock prices should consider IBB because of its risk-reward profile and the long-term prospects of the companies the fund has invested in.

If you enjoyed this article and wish to receive updates on my latest research, click "Follow" next to my name at the top of this article.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

See the original post here:
A Bear Turning Bull On IBB Based On Recent Developments - Seeking Alpha

The latest Blue Biotechnology market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thorough analysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Blue Biotechnology market.

The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of Blue Biotechnology market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00006428/?

Blue biotechnology refers to the use of marine bio-resources as the source of biological applications. Blue biotechnology is used in various applications such as preservation of marine species, restoration of the aquatic wildlife in its original habitat. This field is also used to develop new medicines as well as conduct genetic study of plants. The increase in commercial applications of blue biotechnology has witnessed growth during the recent years, due to the adaptive nature of marine resources.

Key Players

The research provides answers to the following key questions:

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Blue Biotechnology market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal according to different segments. The report also predicts the influence of different industry aspects on the Blue Biotechnology market segments and regions.

by Product (Biopolymers, Bulk Chemicals, Enzymes, Pharma Products, and Other Products); Application (Bio-Engineering, Drug Discovery, Genomics, Vaccine Development, and Other Applications); End User (Biotechnology Companies, Pharmaceutical Companies, Hospitals, Research Institutes & Laboratories, and Other End Users)

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00006428/

Blue Biotechnology Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Originally posted here:
Blue Biotechnology Market Insights, Future Trends, On-going Demand, Opportunities, Segmentation, and Forecast till 2027 - Jewish Life News

In the wake of increasing cases of coronavirus in the city, Panjab University has offered its services to the administration for testing Covid-19 samples.

PU registrar Karamjeet Singh, in a letter to director health services wrote, The teachers fraternity of PU can help the administration in many different areas, including testing of Covid-19 samples,

PU said the departments of microbiology and biotechnology have requisite facilities to test samples using RT-PCR instrument and the BSL-2 (biological safety level-2) laboratory with negative pressure (requirement for testing such samples).

The varsity has offered help from trained research scholars, if the administration provides them standard kits and personal protection equipment (PPE).

We have the infrastructure at our department to help the Chandigarh administration in testing Covid-19 samples, said a professor of the microbiology department.

PU vice-chancellor Raj Kumar said, During this pandemic, we feel it is our duty to assist the Chandigarh administration. Since we have the infrastructure and scientists available, we must utilise them in the public interest.

PUs BioNEST gets funds for research

Panjab Universitys BioNEST has received 6 lakh from Techinvention Lifecare Private Limited, a Mumbai-based private Biotechnology firm, for research on Covid-19.

Rohit Sharma, the project leader of BioNEST-PU said, Such collaborations help in utilising the bio-incubator as a place for dedicated research to provide services in the national interest.

See the original post:
Panjab University offers to help Chandigarh admn in testing of Covid-19 samples - Hindustan Times

New Jersey, United States:The Nanoparticles in Biotechnology and Pharmaceuticals Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Nanoparticles in Biotechnology and Pharmaceuticals market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Nanoparticles in Biotechnology and Pharmaceuticals Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Nanoparticles in Biotechnology and Pharmaceuticals market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Nanoparticles in Biotechnology and Pharmaceuticals market.

The main players featured in the Nanoparticles in Biotechnology and Pharmaceuticals market report are:

Leading players of the Nanoparticles in Biotechnology and Pharmaceuticals market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Nanoparticles in Biotechnology and Pharmaceuticals market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Nanoparticles in Biotechnology and Pharmaceuticals market. It also provides useful recommendations for new as well as established players of the Nanoparticles in Biotechnology and Pharmaceuticals market.

Nanoparticles in Biotechnology and Pharmaceuticals Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Nanoparticles in Biotechnology and Pharmaceuticals market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Nanoparticles in Biotechnology and Pharmaceuticals.

Analysts who have authored the report have segmented the market for Nanoparticles in Biotechnology and Pharmaceuticals by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Nanoparticles in Biotechnology and Pharmaceuticals market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=SGN&utm_medium=003

Highlights of TOC:

Overview: In addition to an overview of the Nanoparticles in Biotechnology and Pharmaceuticals market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Nanoparticles in Biotechnology and Pharmaceuticals.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Nanoparticles in Biotechnology and Pharmaceuticals.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Nanoparticles in Biotechnology and Pharmaceuticals market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Nanoparticles in Biotechnology and Pharmaceuticals market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=SGN&utm_medium=003

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Our Trending Reports

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original here:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and...

New Jersey, United States:The Agricultural Biotechnology Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Agricultural Biotechnology market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Agricultural Biotechnology Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Agricultural Biotechnology market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Agricultural Biotechnology market.

Global Agricultural Biotechnology Market was valued at USD 35.6 Billion in 2018 and is projected to reach USD 74.92 Billion by 2026, growing at a CAGR of 9.70% from 2019 to 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=35624&utm_source=SGN&utm_medium=009

The main players featured in the Agricultural Biotechnology market report are:

Leading players of the Agricultural Biotechnology market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Agricultural Biotechnology market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Agricultural Biotechnology market. It also provides useful recommendations for new as well as established players of the Agricultural Biotechnology market.

Agricultural Biotechnology Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Agricultural Biotechnology market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Agricultural Biotechnology.

Analysts who have authored the report have segmented the market for Agricultural Biotechnology by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Agricultural Biotechnology market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=SGN&utm_medium=009

Highlights of TOC:

Overview: In addition to an overview of the Agricultural Biotechnology market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Agricultural Biotechnology.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Agricultural Biotechnology.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Agricultural Biotechnology market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Agricultural Biotechnology market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=SGN&utm_medium=009

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Agricultural Biotechnology Market Size, Agricultural Biotechnology Market Trends, Agricultural Biotechnology Market Forecast, Agricultural Biotechnology Market Growth, Agricultural Biotechnology Market Analysis

Our Trending Reports

Threat Intelligence Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Agricultural Biotechnology Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 -...

Global Agriculture Biotechnology Market 2019, this report is prepared by in-depth analysis of historical data. The report forecasts the market size by the end of 2026 at an impressive CAGR provided by Reports and Reports. The report offers detailed outline of Agriculture Biotechnology Market and vital market trends. The prime agenda of this report is to provide a detailed analysis of the global, regional and country-level market size, market growth, market status, forecast, sales analysis, value chain optimization, trade regulations, recent developments, opportunities analysis, and importance of the global and national market players, competitive environment, expansion, acquisition, partnerships and technological innovations. The prime market segments considered to prepare this report are key players, regional segments, type and application.

Get Free Sample Copy of Agriculture Biotechnology Market: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/#RequestSample

The Agriculture Biotechnology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The major players covered in Agriculture Biotechnology Market are: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto.

Agriculture Biotechnology Industry 2020 Global Market Research report presents an in-depth analysis of the Agriculture Biotechnology market size, growth, share, segments, manufacturers, and technologies, key trends, market drivers, challenges, standardization, deployment models, opportunities, future roadmap and 2026 forecast. The report additionally presents forecasts for Agriculture Biotechnology market revenue, consumption, production, and growth drivers of the market.

Get Special Discount on this report: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/#AskForDiscount

Regions and Countries Level Analysis:

The important regions, considered to prepare this report are North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The region wise data analyses the trend, market size of each regions Agriculture Biotechnology Market.

Table of Content (TOC)

Chapter 1: Product definition, type and application, Global market overview;

Chapter 2: Global Market competition by company;

Chapter 3: Global sales revenue, volume and price by type;

Chapter 4: Global sales revenue, volume and price by application;

Chapter 5: United States export and import;

Chapter 6: Company information, business overview, sales data and product specifications;

Chapter 7: Industry chain and raw materials;

Chapter 8: SWOT and Porters Five Forces;

Chapter 9: Conclusion.

Continue

List of Tables and Figures

Get Detail information of this report: http://www.milliondollarresearch.com/agriculture-biotechnology-market/955/

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Agriculture Biotechnology Market forecast of till 2026. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

Follow this link:
Global Agriculture Biotechnology Market Expected to Witness the Highest Growth with ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury...

Text Size:A- A+

New Delhi:A leading scientist at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in New Delhi has found that valproic acid, an anti-epilepsy drug, can be repurposed and used for acute cases of Covid-19.

The scientist, Neel Sarovar Bhavesh, has written to the director general of the Indian Council of Medical Research (ICMR), the apex body in the field, to test valproic acid at the National Institute of Virology in Pune or any ICMR lab to find a quick solution to the coronavirus crisis.

The ICGEB is part of the research consortium working to find a cure and vaccine for Covid-19.

Valproic acid is an approved drug, whose patent expired recently. It is sold under brand names such as Depacon and Stavzor to treat epilepsy. The University of California has also validated the ICGEBs research findings it lists valproic acid as one of the molecules for repurposing and testing for use against the Covid-19 virus.

Also read: AI identifies potential drugs and a DNA vaccine in the works latest on Covid-19

Bhavesh, the head of transcriptional regulation at ICGEB, told ThePrint: We have performed high-throughput virtual screening (HTVS) of 1.2 million small molecules from the four databases, and later performed Energy calculation and molecular binding simulation. We found that valproic acid CoA may be repurposed to inhibit the RNA-dependent RNA polymerase of the virus.

We have written to the DG ICMR to test this molecule on cell culture and animal testing facilities, in combination with potent binding blocking molecules. Currently no one in India outside the NIV and ICMR has access to the Covid-19 virus, Bhavesh said.

About 1,100 strains of the novel coronavirus have been sequenced from around the world. We (in India) have around 700 confirmed positive cases, but only two virus sequences are available at the NIV. These sequences are different from each other, he explained.

Bhavesh revealed that after the publication of the ICGEB research, multinational pharmaceutical company GlaxoSmithKline contacted them.

However, Bhavesh said theres an urgent need for cooperation from government bodies like the ICMR and the NIV in terms of giving researchers access to the virus strains in India to test on.

There should be synchronisation in testing and developing. If NIV or any another research institution finds success, lots of patients can be cured and saved. The need of the hour is to find the solution. The NIV must cooperate with other institutions more generously, he said.

A day before, Union Biotechnology Secretary Renu Swarup also said in an interview that early solutions for the novel coronavirus can be found from repurposed drugs, and that developing new drugs would take time.

Also read: Old drugs, new trials hopes pinned on HIV, malaria, ebola, TB vaccines to fight Covid-19

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

Go here to see the original:
Scientist says anti-epilepsy drug can be repurposed for Covid-19, writes to ICMR to test it - ThePrint